London-based venture capital firm, QVentures announces to have backed Britain’s fastest-growing genomics company, Congenica’s Series C round of funding. QVenture’s investment follows an initial round of investment in November 2020.
In the month of November 2020, Congenica raised £39 million which was led by Legal & General and Tencent, alongside investors such as Parkwalk, Cambridge Innovation Capital, Downing, Xeraya, Puhua Capital, and IDO Investments.
The software enabling data analysis
Congenica’s genomic study of rare diseases and inherited cancer and development of software to process the data analysis 20x faster than industry averages. It’s sophisticated software, and data systems enable the analysis and interpretation of complex genomic data. Their mission statement is to make personalised medicine a routine part of healthcare.
Its expertise in genomic study analysis helped them roaring on global footprints. Congenica established a diverse customer base of hospitals, laboratories, pharmaceutical companies and academic medical centres spreading in 19 countries across Europe, North America, Asia and the Middle East.
Robert Walsh, Managing Partner at QVentures said, “We are thrilled to be supporting Congenica in developing their world-leading technology to deliver life-changing answers. At QVentures, we strive to support cutting-edge technology companies that really change how an industry operates, and we believe David and his team are doing just that. We pleased that QVentures’ Family Offices and UHNWI investors could join us on that journey.”
Congenica’s potential in personalised health assessment based on genomic study interpretation and analysis will lead to personalised medical treatment. It’s software led us to implement a more personalised health assessment quickly on daily routine life based on genomic data interpretation & analysis.